© 2001 by Oxford University Press
Journal of the National Cancer Institute Monographs, No. 30, 36-43,
2001
© 2001 Oxford University Press
Efficacy of Systemic Adjuvant Therapy for Breast Cancer in African-American and Caucasian Women
Affiliations of author: Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, and Department of Health Studies, University of Chicago, IL
Correspondence to: James J. Dignam, Ph.D., Department of Health Studies, 5841 South Maryland Ave., MC 2007, University of Chicago, Chicago, IL 60637 (e-mail: jdignam{at}health.bsd.uchicago.edu).
Observed variations in breast cancer survival by racial/ethnic background have been attributed to many factors, including differences in clinical and pathologic disease features at diagnosis and economic resource inequities that may affect treatment access and quality. In this report, we examine outcomes for African-American and Caucasian breast cancer patients participating in selected randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine whether prognosis or efficacy of systemic adjuvant therapy differed between these groups. Randomized clinical trials offer the advantages of a similar disease stage and a uniform treatment plan for all participants. Patients from four NSABP trials enrolling patients from 1982 through 1994 with axillary lymph node-negative disease (543 African-American and 7582 Caucasian) and three trials enrolling patients from 1984 through 1991 with axillary lymph node-positive disease (548 African-American and 4986 Caucasian) were included. Disease-free survival (DFS), which was defined as time on study free of breast cancer recurrence, second primary cancer, or death preceding these events, and survival risk ratios (RRs) with two-sided 95% confidence intervals (CIs) for African-Americans versus Caucasians were computed from Cox proportional hazards models that included relevant prognostic covariates. Treatment benefits for the therapies evaluated in these trials were estimated separately for African-Americans and for Caucasians. Among patients with lymph node-negative disease, African-Americans had similar DFS rates to Caucasians (African-American/Caucasian RR = 1.06, 95% CI = 0.92 to 1.23) but had modestly greater mortality rates (RR = 1.21, 95% CI = 1.01 to 1.46). Among lymph node-positive patients, DFS was similar (RR = 1.04, 95% CI = 0.93 to 1.17) and survival was again less favorable for African-Americans (RR = 1.18 95% CI = 1.03 to 1.34). Survival excluding deaths most likely attributable to causes other than cancer was similar between African-Americans and Caucasians (RR = 1.08 [95% CI = 0.88 to 1.33] for lymph node-negative patients and RR = 1.09 [95% CI = 0.96 to 1.25] for lymph node-positive patients). Among lymph node-negative and lymph node-positive patients, African-Americans and Caucasians realized comparable benefit from either the addition of chemotherapy or tamoxifen to surgery alone or the addition of chemotherapy to tamoxifen. In summary, African-American women and Caucasian women who were diagnosed at a comparable disease stage and were similarly treated tended to experience similar breast cancer prognosis. However, a mortality deficit persisted for African-American women relative to Caucasian women, which may be in part due to greater mortality from noncancer causes among African-Americans. Benefit from systemic adjuvant therapy for recurrence and mortality reduction was comparable between African-Americans and Caucasians. This study and investigations in other health-care settings suggest that African-American women and Caucasian women with breast cancer derive a similar benefit from systemic adjuvant therapy when it is administered in accordance with their clinical and pathologic disease presentation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Dignam Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group J Natl Cancer Inst, January 14, 2010; (2010) djp505v1. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Unger and k. S. Albain Response J Natl Cancer Inst, January 14, 2010; (2010) djp509v1. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Rosenberg, I. Menashe, I. Jatoi, and W. F. Anderson Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group J Natl Cancer Inst, January 14, 2010; (2010) djp510v1. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dawood and A. M. Gonazalez-Angulo Reply to A. Balmanoukian et al J. Clin. Oncol., August 1, 2009; 27(22): e38 - e39. [Full Text] [PDF]
|
|
|
|
|
|
I. Menashe, W. F. Anderson, I. Jatoi, and P. S. Rosenberg Underlying Causes of the Black-White Racial Disparity in Breast Cancer Mortality: A Population-Based Analysis J Natl Cancer Inst, July 15, 2009; 101(14): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Anderson, I. Wapnir, J. J. Dignam, B. Fisher, E. P. Mamounas, J.-H. Jeong, C. E. Geyer Jr, D. L. Wickerham, J. P. Costantino, and N. Wolmark Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2466 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Harper, J. Lynch, S. C. Meersman, N. Breen, W. W. Davis, and M. C. Reichman Trends in Area-Socioeconomic and Race-Ethnic Disparities in Breast Cancer Incidence, Stage at Diagnosis, Screening, Mortality, and Survival among Women Ages 50 Years and Over (1987-2005) Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 121 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Freedman and E. P. Winer Reducing Disparities in Breast Cancer Care--A Daunting but Essential Responsibility J Natl Cancer Inst, December 3, 2008; 100(23): 1661 - 1663. [Full Text] [PDF]
|
|
|
|
|
|
B. N. Polite, C. Cirrincione, G. F. Fleming, D. A. Berry, A. Seidman, H. Muss, L. Norton, C. Shapiro, K. Bakri, K. Marcom, et al. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B J. Clin. Oncol., June 1, 2008; 26(16): 2659 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Moy, D Tu, J. Pater, J. Ingle, L. Shepherd, T. Whelan, and P. Goss Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Ann. Onc., November 1, 2006; 17(11): 1637 - 1643. [Abstract] [Full Text] [PDF]
|
|